BA.3.2, informally known as “Cicada,” is a subvariant of the Omicron family of COVID-19 currently under monitoring by the World Health Organization. While detected in over a dozen countries, it has not been classified as a variant of concern and represents less than 5% of recent submitted sequences, indicating a limited global share. Symptoms associated with BA.3.2 are primarily upper respiratory and consistent with other recent COVID variants, such as sore throat, runny nose, and fatigue.
Read More
A new COVID-19 variant, BA.3.2, has been detected across the United States, suggesting a wider spread than initially observed. This variant, which originated in South Africa in 2024, exhibits significant genetic changes in its spike protein, potentially allowing it to evade immunity from current vaccines. While not yet dominant, BA.3.2’s genetic distinctiveness from prevailing JN.1 subvariants necessitates monitoring and potential updates to vaccination strategies. Although initial findings in hospitalized patients have not indicated increased severity, the ongoing mutation of the virus underscores the importance of continued vigilance and public health preparedness.
Read More
John Q. Hosedrinker